Browsing: PI3KAKTmTOR

Treatments

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

By NewsCancerMay 28, 20260

BackgroundThe PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM…

Support

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1

By NewsCancerMay 27, 20260

BackgroundThe PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM…

What's Hot

From ambition to delivery: is the National Cancer Plan properly funded? – Cancer Research UK

Why I Always Thought Other People Were Upset with Me

FDA Approves Topical Gel for Superficial Basal Cell Carcinoma

Browsing: PI3KAKTmTOR

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1

From ambition to delivery: is the National Cancer Plan properly funded? – Cancer Research UK

Why I Always Thought Other People Were Upset with Me

FDA Approves Topical Gel for Superficial Basal Cell Carcinoma

FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC

From ambition to delivery: is the National Cancer Plan properly funded? – Cancer Research UK

Why I Always Thought Other People Were Upset with Me

FDA Approves Topical Gel for Superficial Basal Cell Carcinoma

FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC

Latest Post

From ambition to delivery: is the National Cancer Plan properly funded? – Cancer Research UK

Why I Always Thought Other People Were Upset with Me

FDA Approves Topical Gel for Superficial Basal Cell Carcinoma

Subscribe to Updates

What's Hot

Browsing: PI3KAKTmTOR